# Table Of Contents

COVID-19 Cases

1-9
COVID-19 Cases

Figure 1.

US COVID-19 (number, 10-day moving average, thousands)

- New Positive Results (55)
- Hospital Patients* (34)

* Note: Data for hospital patients from July 2020 to the present is from Oxford University, prior to that data is from COVID Tracking Project.
Source: Department of Health & Human Services, Centers for Disease Control & Prevention, COVID Tracking Project and Oxford University.

Figure 2.

US COVID-19 (number, 10-day moving average, thousands)

- Deaths (15243)

Source: European Centre for Disease Prevention and Control.
Figure 3.

UK COVID-19
(number, 10-day moving average, thousands)

New Cases (5.1)
Hospital Patients (5.1)

Source: Oxford University.

Figure 4.

FRANCE COVID-19
(number, 10-day moving average, thousands)

New Cases (36.8)
Hospital Patients (26.1)

Source: Oxford University.
COVID-19 Cases

Figure 5.

ITALY COVID-19
(number, 10-day moving average, thousands)

- New Cases (21.3)
- Hospital Patients (30.8)

Source: Oxford University.

Figure 6.

GERMANY COVID-19
(number, 10-day moving average, thousands)

- New Cases (19)

Source: Oxford University.
Figure 7.

SPAIN COVID-19
(number, 10-day moving average, thousands)

New Cases (8)

Source: Oxford University.

Figure 8.

JAPAN COVID-19
(number, 10-day moving average, thousands)

New Cases (2)

Source: Oxford University.
COVID-19 Cases

Figure 9.

**BRAZIL COVID-19**
(number, 10-day moving average, thousands)

Source: Oxford University.

Figure 10.

**MEXICO COVID-19**
(number, 10-day moving average, thousands)

Source: Oxford University.
**Figure 11.**

**INDIA COVID-19**
(number, 10-day moving average, thousands)

New Cases (57)

Source: Oxford University.

**Figure 12.**

**CHINA COVID-19**
(number, 10-day moving average, thousands)

New Cases (0)

Source: Oxford University.
* Newly positive percent of new test results. Ten-day moving average. New test results data do not include pending tests, which are not yet indicative of a positive or negative result. A positivity rate of 5% or below is considered a sufficient scope of testing for COVID-19 as per the World Health Organizations guidance.

Source: COVID Tracking Project.
Figure 14.

**US COVID-19 CASES**
(number, 10-day moving average)

New Positive Tests Results In Thousands (65)

New Tests In Thousands (1485)

Positivity Rate In Percent* (4.5)

*Newly positive percent of new test results. Ten-day moving average. New test results data do not include pending tests, which are not yet indicative of a positive or negative result. A positivity rate of 5% or below is considered a sufficient scope of testing for COVID-19 as per the World Health Organizations guidance.

Source: COVID Tracking Project.
US COVID-19 CASES
(number, 10-day moving average, thousands)

COVID TRACKING DATA
Cases Minus New Positive Tests

* Cumulative daily change, 10-day average.
Source: COVID Tracking Project.
Copyright (c) Yardeni Research, Inc. 2021. All rights reserved. The information contained herein has been obtained from sources believed to be reliable, but is not necessarily complete and its accuracy cannot be guaranteed. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness, or correctness of the information and opinions contained herein. The views and the other information provided are subject to change without notice. All reports and podcasts posted on www.yardeni.com, blog.yardeni.com, and YRI’s Apps are issued without regard to the specific investment objectives, financial situation, or particular needs of any specific recipient and are not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not necessarily a guide to future results. Company fundamentals and earnings may be mentioned occasionally, but should not be construed as a recommendation to buy, sell, or hold the company’s stock. Predictions, forecasts, and estimates for any and all markets should not be construed as recommendations to buy, sell, or hold any security--including mutual funds, futures contracts, and exchange traded funds, or any similar instruments.

The text, images, and other materials contained or displayed on any Yardeni Research, Inc. product, service, report, email or website are proprietary to Yardeni Research, Inc. and constitute valuable intellectual property. No material from any part of www.yardeni.com, blog.yardeni.com, and YRI’s Apps may be downloaded, transmitted, broadcast, transferred, assigned, reproduced or in any other way used or otherwise disseminated in any form to any person or entity, without the explicit written consent of Yardeni Research, Inc. All unauthorized reproduction or other use of material from Yardeni Research, Inc. shall be deemed willful infringement(s) of this copyright and other proprietary and intellectual property rights, including but not limited to, rights of privacy. Yardeni Research, Inc. expressly reserves all rights in connection with its intellectual property, including without limitation the right to block the transfer of its products and services and/or to track usage thereof, through electronic tracking technology, and all other lawful means, now known or hereafter devised. Yardeni Research, Inc. reserves the right, without further notice, to pursue to the fullest extent allowed by the law any and all criminal and civil remedies for the violation of its rights.

The recipient should check any email and any attachments for the presence of viruses. Yardeni Research, Inc. accepts no liability for any damage caused by any virus transmitted by this company’s emails, website, blog and Apps. Additional information available on request.